RECIST 1.1 Compared With RECIST 1.0 in Patients With Advanced Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor-Targeted Therapy

被引:19
|
作者
Krajewski, Katherine M. [1 ,2 ]
Nishino, Mizuki [1 ,2 ]
Ramaiya, Nikhil H. [1 ,2 ]
Choueiri, Toni K. [3 ,4 ]
机构
[1] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst,Dept Imaging, Boston, MA 02115 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA
[3] Dana Farber Canc Inst, Kidney Canc Ctr, Boston, MA 02115 USA
[4] Brigham & Womens Hosp, Boston, MA 02115 USA
关键词
CT; renal cell carcinoma; Response Evaluation Criteria in Solid Tumors (RECIST); tumor response assessment; vascular endothelial growth factor-targeted therapy; RESPONSE EVALUATION CRITERIA; COMPUTED-TOMOGRAPHY; TUMOR RESPONSE; ATTENUATION; EVALUATE; SIZE; COEFFICIENT; GUIDELINES; INHIBITORS; SUNITINIB;
D O I
10.2214/AJR.14.13236
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
OBJECTIVE. Response Evaluation Criteria in Solid Tumors (RECIST) is the most widely accepted method to objectively assess response to therapy in renal cell carcinoma (RCC) treated with vascular endothelial growth factor (VEGF)-targeted therapy. Both RECIST 1.0 and 1.1 have been used to assess response to VEGF-targeted therapies; however, systematic comparisons are lacking. MATERIALS AND METHODS. Sixty-two patients with metastatic RCC treated with VEGF-targeted therapies were retrospectively studied. Tumor measurements and response assessment according to RECIST 1.1 and RECIST 1.0 were compared, including the number of target lesions, baseline measurements, response at each follow-up, best overall response, and time to progression (TTP). Morphologic changes and new enhancement were also assessed over the course of treatment, and TTP was evaluated using morphologic change criteria in combination with RECIST 1.1. RESULTS. The number of target lesions according to RECIST 1.1 was significantly fewer than by RECIST 1.0 (median, 2 vs 4; p < 0.0001). At first imaging follow-up, the percentage change of the sums of the diameter measurements by RECIST 1.1 and RECIST 1.0 were highly concordant (R = 0.857; mean shrinkage, 12.1% by RECIST 1.1 vs 10.8% by RECIST 1.0). Best response assessment was highly concordant between the two criteria (weighted. = 0.819). There was no evidence of a difference in TTP by the two criteria, with a median TTP of 8.9 months (95% CI for the median, 5.5-13.9) by RECIST 1.1 and 8.9 months (95% CI for the median, 5.8-13.6) by RECIST 1.0. The median TTP by RECIST 1.1 alone was 8.9 months compared with 5.6 months for RECIST 1.1 and morphologic changes combined. CONCLUSION. RECIST 1.1 and RECIST 1.0 response assessments were overall highly concordant in patients with RCC treated with VEGF-targeted therapy, with fewer target lesions according to RECIST 1.1 but no difference in TTP.
引用
收藏
页码:W282 / W288
页数:7
相关论文
共 50 条
  • [1] Vascular Endothelial Growth Factor-Targeted Therapies in Advanced Renal Cell Carcinoma
    Albiges, Laurence
    Salem, Mohamed
    Rini, Brian
    Escudier, Bernard
    [J]. HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2011, 25 (04) : 813 - +
  • [2] Conditional survival in patients treated with vascular endothelial growth factor-targeted therapy for advanced renal cell carcinoma
    Zhu, Y.
    Hong, Y. P.
    Zhang, H. L.
    Shi, G. H.
    Xiao, W. J.
    Wang, Z. H.
    Yao, X. D.
    Zhang, S. L.
    Dai, B.
    Ye, D. W.
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (11) : 1901 - 1907
  • [3] Vascular Endothelial Growth Factor-targeted Therapy in Metastatic Renal Cell Carcinoma
    Rini, Brian I.
    [J]. CANCER, 2009, 115 (10) : 2306 - 2312
  • [4] Conditional survival in patients treated with vascular endothelial growth factor-targeted therapy for advanced renal cell carcinoma
    Y. Zhu
    Y. P. Hong
    H. L. Zhang
    G. H. Shi
    W. J. Xiao
    Z. H. Wang
    X. D. Yao
    S. L. Zhang
    B. Dai
    D. W. Ye
    [J]. Journal of Cancer Research and Clinical Oncology, 2012, 138 : 1901 - 1907
  • [5] Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Renal Cell Carcinoma
    Escudier, Bernard
    Albiges, Laurence
    [J]. DRUGS, 2011, 71 (09) : 1179 - 1191
  • [6] Vascular Endothelial Growth Factor-Targeted Therapy for the Treatment of Renal Cell Carcinoma
    Bernard Escudier
    Laurence Albiges
    [J]. Drugs, 2011, 71 : 1179 - 1191
  • [7] Comparison of Four Early Posttherapy Imaging Changes (EPTIC; RECIST 1.0, Tumor Shrinkage, Computed Tomography Tumor Density, Choi Criteria) in Assessing Outcome to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Advanced Renal Cell Carcinoma
    Krajewski, Katherine M.
    Guo, Mengye
    Van den Abbeele, Annick D.
    Yap, Jeffrey
    Ramaiya, Nikhil
    Jagannathan, Jyothi
    Heng, Daniel Y. C.
    Atkins, Michael B.
    McDermott, David F.
    Schutz, Fabio A. B.
    Pedrosa, Ivan
    Choueiri, Toni K.
    [J]. EUROPEAN UROLOGY, 2011, 59 (05) : 856 - 862
  • [8] Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma
    Rini, BI
    Small, EJ
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (05) : 1028 - 1043
  • [9] Metastatic Sarcomatoid Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor-Targeted Therapy
    Golshayan, Ali Reza
    George, Saby
    Heng, Daniel Y.
    Elson, Paul
    Wood, Laura S.
    Mekhail, Tarek M.
    Garcia, Jorge A.
    Aydin, Hakan
    Zhou, Ming
    Bukowski, Ronald M.
    Rini, Brian I.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (02) : 235 - 241
  • [10] Prognostic Biomarkers for Response to Vascular Endothelial Growth Factor-Targeted Therapy for Renal Cell Carcinoma
    Winer, Andrew G.
    Motzer, Robert J.
    Hakimi, A. Ari
    [J]. UROLOGIC CLINICS OF NORTH AMERICA, 2016, 43 (01) : 95 - +